Muscle problems affect over one-third of NMOSD patients: Study
A review of nearly 100 articles found that muscle problems are relatively common in NMOSD, affecting more than one-third of patients.| Neuromyelitis News
A review of nearly 100 articles found that muscle problems are relatively common in NMOSD, affecting more than one-third of patients.| Neuromyelitis News
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Neuromyelitis News
The activity of an immune-regulating protein is significantly lower just before or during a relapse in people with neuromyelitis optica spectrum disorder (NMOSD), a recent study has found. This discovery could lead to new ways to monitor disease activity and develop treatments. The protein, called the aryl hydrocarbon receptor (AHR), is a ligand-activated transcription factor. […] The post AHR protein may be a biomarker for NMOSD relapses appeared first on Neuromyelitis News.| Neuromyelitis News – The Web's Daily Resource for Neuromyelitis Optica News
Long-term use of the approved therapy Enspryng (satralizumab) safely and effectively prevented relapses in people with neuromyelitis optica spectrum disorder (NMOSD) who have antibodies against aquaporin-4 (AQP4). That’s according to up to 8.8 years of pooled data from two placebo-controlled Phase 3 clinical trials — SAkuraStar (NCT02073279) and SAkuraSky (NCT02028884) — and their now-completed open-label extension study, […] The post Enspryng prevents relapses in NMOSD for up to ne...| Neuromyelitis News – The Web's Daily Resource for Neuromyelitis Optica News
Category archive page for News.| Neuromyelitis News
Sex ratio and age at onset among NMOSD patients are influenced by the proportion of cases with anti-AQP4 antibodies, a review study found.| Neuromyelitis News
